



MATRIXYL[®] Morphomics[®]



It's time to shape the skin's future



before



after 6 weeks

6 weeks to turn marionette lines into a smile

FORMULATION water soluble

Add in the formula between room temperature and 50°C.

RECOMMENDED USE LEVEL 2%

PATENT FR3029782–WO2016/097965–US11,612,556–EP3256102–JP2018500330–
JP 2018500330 – JP 2022019764 – CN 106999401 – CN 113264984 –
KR 10-2655355 – BR 11 2017 012474 2 – MX 403000

INCI NAME Water (Aqua) – Pentylene Glycol – Caprylyl Glycol –
N-Prolyl Palmitoyl Tripeptide-56 Acetate

FUNCTION Anti-wrinkle.


DEFINITION A novel approach in the research of active matrikines[®]: Palmitoylated tripeptide Lysyl-Histidyl-Glycine with a grafted proline on the lysine.

PROPERTIES MATRIXYL[®] Morphomics[®] supports the reduction of vertical lines (frown lines, marionette lines, nasogenian fold) but also crow's feet after 6 weeks, for a happier expression.

CHARACTERISTICS MATRIXYL[®] Morphomics[®] influences cellular and dermal morphology by re-establishing and rebooting the skin connections between the fibroblast nucleus and the ECM.

POINT OF INTEREST Proteomics of Youth[®] reveal the activation of longevigenes[®] against signs of ageing.

APPLICATIONS Anti-ageing creams, serums, gels...



FACE

www.crodabeauty.com
beauty@croda.com
© Copyright 17-2025

CRODA
Beauty Actives




2-0024-06-100-04

CLAIM SUBSTANTIATION

in vitro

REBOOTING THE CONNECTION: THE CYTOSKELETON




Cofilin	+446%* (3)	+95%*** (4)
α-Actinin-1	+82%*** (4)	
Actin eq.1 %	+187%* (3)	
Talin 2 %	+65.8%* (1)	
Integrin α2/β1 eq.1.4 %	+55.3%* (2)	
Fibronectin eq.1.4 %	+61%* (5)	

TECHNOLOGIES:

- (1) Explants + immunohistology MATRIXYL®Morphomics® eq.2%
- (2) Skin equivalents + immunohistology

- (3) Normal human fibroblast cultures + immunocytology
- (4) Proteomics (LC-MSMS) MATRIXYL®Morphomics® eq.1%
- (5) Normal human fibroblast cultures + Elisa
- (6) qRT-PCR, MATRIXYL® Morphomics® eq. 1%

SIGNIFICANCE: * p<0.01/control or placebo, ** p<0.02/control, *** p<0.05/control or placebo




MATRIXYL® Morphomics® reboots the connection between the nucleus and the ECM by ensuring the cytoskeleton integrity.


DERMAL MORPHOLOGY

	gene (4)	protein	fibre (1)
COLLAGEN I	x 1.81*	+42%*	+14.3%***
Protein disulfide isomerase (PDI)		+45%*	
Prolyl 4-hydroxylase subunit alpha-1 (P4HA1)	x 1.53*	+74%*	
Procollagen-lysin, 2-oxoglutarate 5-dioxygenase (PLOD1)	x 2.03*	+43%***	
Pro-collagen gluco-galactosyl-transferase1 (COLGALT1)	x 1.94*	+161%*	
N-proteinase (ADAMTs1)		+72%**	
Procollagen C-endopeptidase enhancer-1 (PCOLCE)	x 1.61*	+62%*	
Plasminogen activator inhibitor-1 (PAI-1)		+54%*	
Matrix metalloproteinase-2 (MMP2)		-54%*	
COLLAGEN III (COL3A1)		+58%*	
COLLAGEN IV	eq.1.4 %	+79%*	
	eq.2 %	+182%*	+12.1%*
COLLAGEN VI (COL6A3)	eq.1.4 %	+113%***	+27%*
	eq.2 %	+45%*	
HYALURONIC ACID			+25%*

Fibrillar Collagen Enzyme Crew



MATRIXYL® Morphomics® stimulates the collagen fibre production and maturation to rebuild a functional network.



MATRIXYL® Morphomics® acts on various key players responsible for the cellular and dermis morphology.

in vivo

CLINICAL STUDIES

2 female panels with mean age 64 and 58 years old and one male panel with mean age 59 years old. Twice daily application of a cream with 2% MATRIXYL® Morphomics® on the face against placebo for 6 weeks.

MARIONETTE LINES


Instrumental evaluation of the marionette lines by FOITS on 26 female panellists.

Volume (mm³) **-22.7 %/T0** up to **-99 %**, **-21.7 %/placebo** p<0.08
Perimeter (mm) **-10.6 %/T0** up to **-92 %**, **-9.6 %/placebo**, p<0.06

FROWN LINES


Instrumental evaluation of the frown lines by FOITS on 2x32 female panellists.

Volume (mm³) **-9.5 %/T0** up to **-65 %**, **-9.2 %/placebo**
Perimeter (mm) **-7.1 %/T0** up to **-39 %**, **-7.8 %/placebo**,
Roughness (Sa in µm) **-5.8 %/T0** up to **-20 %**, **-3.9 %/placebo**,




RECOVERY AFTER FROWNING

Instrumental evaluation of the skin smoothness recovery after frowning for 10 seconds by FOITS on 22 female panellists.



VISIBLE REDUCTION OF VERTICAL LINES

Evaluation of the vertical line perception by 5 expert judges on 34 female panellists.



MATRIXYL® Morphomics® exerts a significantly perceivable effect on reducing vertical lines compared to the placebo, especially the frown lines.

CROW'S FEET

Instrumental evaluation of the crow's feet by FOITS on 32 female panellists and on 20 male panellists.

Main wrinkle volume (mm³) **-16.5 %/T0** up to **-52 %**, **-7.1 %/placebo**, p<0.07
Mean depth (µm) **-13.5 %/T0** up to **-44 %**, **-7.3 %/placebo**, p<0.01
Deep wrinkles surface (%) **-26.6 %/T0** up to **-75 %**, **-14.3 %/placebo**, p<0.06
Roughness (µm) **-9.9 %/T0** up to **-30 %**, **-4.9 %/placebo**, p<0.05
Wrinkle width angle (°) **+16.4 %/T0** up to **+45 %**, **+15.2 %/placebo**, p<0.01



Wrinkle surface (mm²) **-11.8 %/T0** up to **-49 %**, **-13.2 %/placebo**, p<0.05